Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study, comparing consecutive high-risk allogeneic H...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2021-04-01
|
| Serija: | Vaccines |
| Teme: | |
| Online pristup: | https://www.mdpi.com/2076-393X/9/4/372 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|